MYRIAD GENETICS INC 8-K

What Happened

• Myriad Genetics, Inc. announced its financial results for the three months ended March 31, 2026 in an earnings release dated May 5, 2026. The earnings release is attached to the Form 8-K as Exhibit 99.1 and is incorporated by reference into the filing.
• The Form 8-K also includes a standard cautionary note that the release contains forward-looking statements that involve risks and uncertainties.

Key Details

• Announcement date: May 5, 2026.
• Reporting period: three months ended March 31, 2026 (Q1 2026).
• Earnings release attached as Exhibit 99.1 to the 8-K.
• Filing includes a forward-looking statements caution; investors should review Exhibit 99.1 for any guidance or projections.

Why It Matters

• This 8-K signals that Myriad has released its quarterly earnings information; those results (revenue, profit/loss, and any guidance) can directly affect the company’s stock and investor decisions.
• The filing does not present the financial line items in the 8-K text itself—investors should read the attached Exhibit 99.1 (the earnings release) for the specific quarterly revenue, earnings, and management commentary.
• The forward-looking statements caution indicates management may have provided outlook or expectations in the release; investors should consider the risks and assumptions disclosed alongside any projections.